A network meta-analysis found vibegron outperformed mirabegron and tolterodine on several OAB efficacy measures but had higher odds of adverse events.
Commentary|Articles|November 5, 2024
Rethinking Diabetes Care: Are New Therapies Adding Value or Cost?
Author(s)Hayden E. Klein
Sanjula Jain, PhD, chief research officer at Trilliant Health, discusses the rapid adoption of glucagon-like peptide 1 inhibitors for diabetes and preventive care for obesity and late-onset diabetes.
Advertisement
Advertisement
The latest report from Trilliant Health examined both the rapid adoption of glucagon-like peptide 1 (GLP-1) inhibitors for
Related to this article
A US modeling study found tirzepatide and semaglutide cost-effective for MASH, while resmetirom exceeded the $100,000/QALY threshold.
Panelists say drug price negotiation, Medicaid changes, prior authorization, and 340B reform strain community oncology.
Symptom-tracking tools may improve awareness and patient-clinician communication but can also add stress.
Payers cover novel cancer drugs but not the staffing, training, and monitoring to deliver them, leaving practices to absorb costs.
The 2026 COA Payer Exchange and Innovation Summit began with a panel on AI and the ever-changing digital infrastructure in community oncology.
Expert panel discussions covered AI and community access, chronic lymphocytic leukemia, myeloma, and breast and lung cancers.
Longer undetectable hepatitis D RNA on bulevirtide predicts durable suppression off therapy, but rebound and ALT flares rise, especially in cirrhosis.
Advertisement
Advertisement